Global Type 1 Diabetes Market 2025-2035

Description

List of Tables

Type 1 Diabetes Treatment Market Size, Share & Trends Analysis Report by Insulin Analog (Rapid-Acting, Long-Acting, and Premix) by Drug Class (Insulin, and Non-Insulin) and by Devices (Insulin Pumps, Insulin Pen, Blood Glucose Meters, and Others), Forecast Period (2025-2035)

Industry Overview

Type 1 diabetes treatment market was valued at $15.5 billion in 2024 and is projected to reach $29.6 billion by 2035, growing at a CAGR of 6.0% during the forecast period (2025-2035). The market growth is driven by increasing disease prevalence, advancements in insulin analogues and delivery devices like insulin pens and closed-loop systems, and growing patient awareness. Its key factors propelling the market include the development of new disease-modifying therapeutics and a rising focus on managing the condition in home care settings. However, challenges like limited health reimbursement and diagnosis rates in emerging countries, in addition to the high cost of novel therapies, can restrict growth.

Market Dynamics

Rising Prevalence of Type 1 Diabetes

The increasing incidence of Type 1 diabetes globally is a significant driver of market growth. Factors such as genetic predisposition, autoimmune responses, and environmental triggers contribute to the rising number of diagnosed cases. This surge in prevalence necessitates the development and availability of effective treatment options, thereby expanding the market for Type 1 diabetes treatments.

Technological Advancements in Treatment Devices

Innovations in diabetes management technologies have transformed treatment approaches. Devices like insulin pumps, continuous glucose monitors (CGMs), and insulin pens offer patients more precise control over their blood glucose levels. These advancements enhance treatment adherence and improve patient outcomes, driving the demand for advanced treatment devices in the market.

Increased Awareness and Early Diagnosis

Raising awareness about Type 1 diabetes symptoms and the importance of early diagnosis has led to more individuals seeking medical attention promptly. Early detection facilitates timely intervention, improving long-term health outcomes and reducing complications. This proactive approach to diabetes care contributes to the growing market for treatments for Type 1 diabetes.

Market Segmentation

Based on the insulin analog, the market is segmented into (rapid-acting, long-acting, and premix.
Based on the network type, the market is segmented into 5G NR standalone (SA) and 5G NR non-standalone (NSA).
Based on the drug class, the market is segmented into insulin and non-insulin.
Based on the technology, the market is segmented into insulin pumps, insulin pens, blood glucose meters, and others.

Rapid-Acting Largest Segment Leading the Global Type 1 Diabetes Treatment Market

Among the various segments within the Type 1 Diabetes Treatment market, insulin analogs-particularly rapid-acting insulin analogs-hold the largest share and lead the global market. Rapid-acting insulins are crucial in regulating postprandial glucose levels, mimicking the body's natural insulin response immediately after meals. Their ability to provide precise glycemic control has made them the preferred choice for both patients and healthcare providers managing Type 1 diabetes. Additionally, rapid-acting insulins are widely used in combination therapies with long-acting insulins, further cementing their dominance in treatment protocols. The high adoption rate is supported by growing awareness of the advantages of analog insulin over traditional human insulin, including better blood sugar management, lower risk of hypoglycemia, and flexibility in dosage schedules. Furthermore, insurance coverage and government initiatives in developed countries, particularly in North America and Europe, have facilitated wider access to these insulin analogs, reinforcing their position as the leading segment in the Type 1 diabetes treatment market.

Insulin Pumps: A Key Segment in Market Growth

The insulin delivery devices segment is one of the most crucial contributors to market growth in the global Type 1 Diabetes Treatment market. This segment includes insulin pumps, insulin pens, continuous glucose monitors (CGMs), and other delivery devices, which have transformed diabetes management over the past decade. Insulin pumps, for instance, provide continuous subcutaneous insulin infusion, offering precise and programmable insulin delivery that closely mimics physiological insulin release. This technology not only improves glycemic control but also enhances patient convenience, compliance, and quality of life. Insulin pens, with their ease of use and accurate dosing capabilities, have significantly simplified insulin administration, making it more accessible to a broader population, including pediatric and elderly patients. Continuous glucose monitors complement these devices by offering real-time blood glucose tracking, alerts for hypo- and hyperglycemia, and integration with smart devices and mobile applications for personalized diabetes management.

Regional Outlook

The global type 1 diabetes treatment market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Asia-Pacific Maintains Strong Market Position

North America holds a significant share of the global type 1 diabetes treatment market. The US dominates the global Type 1 Diabetes Treatment market, holding a significant share of the overall market revenue. In 2024, North America accounted for nearly 40% of the global market, with the US being the primary contributor due to its advanced healthcare infrastructure, high prevalence of Type 1 diabetes, and early adoption of innovative treatment technologies. The country benefits from widespread availability of insulin analogs, insulin delivery devices such as pumps and pens, and continuous glucose monitoring systems, which are increasingly integrated with digital health platforms for real-time patient management.

Additionally, strong government support, well-established reimbursement policies, and awareness programs further drive the adoption of effective diabetes management solutions. The presence of major pharmaceutical companies such as Eli Lilly, Novo Nordisk, Sanofi, and AstraZeneca also contributes to the United States' dominant position, as these companies continuously innovate, launch new products, and expand access to advanced therapies.

Moreover, ongoing research and clinical trials in the country accelerate the development of next-generation treatment options, reinforcing the U.S. as the global leader in the Type 1 Diabetes Treatment market. Emerging trends such as personalized medicine and connected insulin delivery devices further consolidate its market dominance, ensuring sustained growth and leadership in the foreseeable future.

Market Players Outlook

The major companies operating in the global type 1 diabetes treatment market include AstraZeneca, Biocon Ltd., Eli Lilly and Co., Novo Nordisk, and Sanofi, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In October 2025, Eli Lilly announced plans to invest over $1 billion in India to expand its manufacturing capacity for diabetes treatments. This move aims to increase the availability of key drugs and strengthen the company's presence in the Asian market.
In September 2025, Aspen Pharmacare received regulatory approval to launch the injector pen version of Mounjaro, Eli Lilly's diabetes drug, in South Africa. This approval is expected to ease current supply shortages and intensify competition in the diabetes treatment market.
In April 2025, Roche partnered with Zealand Pharma to develop and commercialize treatments for obesity using Zealand's experimental drug petrelintide. This strategic move aims to offer new treatment options for people with obesity and related conditions, entering a market dominated by Novo Nordisk and Eli Lilly.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global type 1 diabetes treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2024008

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Type 1 Diabetes Treatment Market Sales Analysis - Insulin Analog | Drug Class | Devices $ Million)
Type 1 Diabetes Treatment Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Type 1 Diabetes Treatment Market Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Type 1 Diabetes Treatment Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Type 1 Diabetes Treatment Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global Type 1 Diabetes Treatment Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Type 1 Diabetes Treatment Market Revenue and Share by Manufacturers
Type 1 Diabetes Treatment Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. AstraZeneca plc
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Biocon Ltd.
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Eli Lilly and Co.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Novo Nordisk
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Sanofi SA
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Type 1 Diabetes Treatment Market Sales Analysis By Insulin Analog ($ Million)

5.1. Rapid-Acting
5.2. Long-Acting
5.3. Premix

6. Global Type 1 Diabetes Treatment Market Sales Analysis By Drug Class ($ Million)

6.1. Insulin
6.2. Non-Insulin

7. Global Type 1 Diabetes Treatment Market Sales Analysis By Devices ($ Million)

7.1. Insulin Pumps
7.2. Insulin Pen
7.3. Blood Glucose Meters
7.4. Others

Regional Analysis

North American Type 1 Diabetes Treatment Market Sales Analysis - Insulin Analog | Drug Class | Devices $ Million)
Macroeconomic Factors for North America
- 7.4.1. United States
- 7.4.2. Canada
European Type 1 Diabetes Treatment Market Sales Analysis - Insulin Analog | Drug Class | Devices $ Million)
Macroeconomic Factors for Europe
- 7.4.3. UK
- 7.4.4. Germany
- 7.4.5. Italy
- 7.4.6. Spain
- 7.4.7. France
- 7.4.8. Russia
- 7.4.9. Rest of Europe
Asia-Pacific Type 1 Diabetes Treatment Market Sales Analysis - Insulin Analog | Drug Class | Devices $ Million)
Macroeconomic Factors for Asia-Pacific
- 7.4.10. China
- 7.4.11. Japan
- 7.4.12. South Korea
- 7.4.13. India
- 7.4.14. Australia & New Zealand
- 7.4.15. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 7.4.16. Rest of Asia-Pacific
Rest of the World Type 1 Diabetes Treatment Market Sales Analysis - Insulin Analog | Drug Class | Devices $ Million)
Macroeconomic Factors for the Rest of the World
- 7.4.17. Latin America
- 7.4.18. Middle East and Africa

8. Company Profiles

8.1. Abbott Laboratories
- 8.1.1. Quick Facts
- 8.1.2. Company Overview
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategies
8.2. AstraZeneca
- 8.2.1. Quick Facts
- 8.2.2. Company Overview
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategies
8.3. Bayer
- 8.3.1. Quick Facts
- 8.3.2. Company Overview
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategies
8.4. Becton Dickinson
- 8.4.1. Quick Facts
- 8.4.2. Company Overview
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategies
8.5. Biocon
- 8.5.1. Quick Facts
- 8.5.2. Company Overview
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategies
8.6. Dexcom
- 8.6.1. Quick Facts
- 8.6.2. Company Overview
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategies
8.7. Eli Lilly
- 8.7.1. Quick Facts
- 8.7.2. Company Overview
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategies
8.8. Insulet Corp.
- 8.8.1. Quick Facts
- 8.8.2. Company Overview
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategies
8.9. Johnson & Johnson
- 8.9.1. Quick Facts
- 8.9.2. Company Overview
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategies
8.10. Medtronic
- 8.10.1. Quick Facts
- 8.10.2. Company Overview
- 8.10.3. Product Portfolio
- 8.10.4. Business Strategies
8.11. Merck & Co.
- 8.11.1. Quick Facts
- 8.11.2. Company Overview
- 8.11.3. Product Portfolio
- 8.11.4. Business Strategies
8.12. Mylan
- 8.12.1. Quick Facts
- 8.12.2. Company Overview
- 8.12.3. Product Portfolio
- 8.12.4. Business Strategies
8.13. Novo Nordisk
- 8.13.1. Quick Facts
- 8.13.2. Company Overview
- 8.13.3. Product Portfolio
- 8.13.4. Business Strategies
8.14. Roche
- 8.14.1. Quick Facts
- 8.14.2. Company Overview
- 8.14.3. Product Portfolio
- 8.14.4. Business Strategies
8.15. Sandoz
- 8.15.1. Quick Facts
- 8.15.2. Company Overview
- 8.15.3. Product Portfolio
- 8.15.4. Business Strategies
8.16. Sanofi
- 8.16.1. Quick Facts
- 8.16.2. Company Overview
- 8.16.3. Product Portfolio
- 8.16.4. Business Strategies
8.17. Tandem Diabetes Care
- 8.17.1. Quick Facts
- 8.17.2. Company Overview
- 8.17.3. Product Portfolio
- 8.17.4. Business Strategies
8.18. Valeritas
- 8.18.1. Quick Facts
- 8.18.2. Company Overview
- 8.18.3. Product Portfolio
- 8.18.4. Business Strategies
8.19. Wockhardt
8.20. Quick Facts
8.21. Company Overview
8.22. Product Portfolio
8.23. Business Strategies